Karyopharm Therapeutics Inc.
KPTI
$4.64
-$0.06-1.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.19% | -0.55% | 1.77% | -0.23% | -5.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.19% | -0.55% | 1.77% | -0.23% | -5.16% |
| Cost of Revenue | -46.55% | 21.55% | 228.27% | 191.79% | 202.42% |
| Gross Profit | 4.29% | -1.32% | -17.11% | -20.38% | -15.73% |
| SG&A Expenses | -9.78% | -12.47% | -14.64% | -14.72% | -11.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.32% | -3.95% | -0.20% | 0.70% | -3.52% |
| Operating Income | 10.17% | 7.79% | 2.43% | -1.76% | 1.72% |
| Income Before Tax | 57.19% | 46.51% | 37.50% | 36.56% | 7.44% |
| Income Tax Expenses | -93.53% | -82.35% | 11.28% | -6.35% | 16.04% |
| Earnings from Continuing Operations | 57.27% | 46.60% | 37.41% | 36.50% | 7.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.27% | 46.60% | 37.41% | 36.50% | 7.39% |
| EBIT | 10.17% | 7.79% | 2.43% | -1.76% | 1.72% |
| EBITDA | 10.20% | 7.68% | 2.26% | -2.03% | 1.42% |
| EPS Basic | 58.05% | 46.21% | 39.69% | 42.84% | 29.06% |
| Normalized Basic EPS | 32.54% | 20.24% | 17.58% | 22.84% | 26.94% |
| EPS Diluted | 30.50% | 18.20% | 13.37% | 19.44% | 29.08% |
| Normalized Diluted EPS | 35.47% | 23.22% | 20.34% | 25.32% | 26.94% |
| Average Basic Shares Outstanding | 8.73% | 6.69% | 10.25% | 17.06% | 26.32% |
| Average Diluted Shares Outstanding | 16.01% | 14.00% | 17.98% | 25.46% | 26.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |